Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Home
Verici Dx Plc
Provider Participation Agreement with Prime Health
Business
Nov 6 2025
4 min read

Provider Participation Agreement with Prime Health

 

Verici Dx plc

("Verici Dx" or the "Company")

 

Provider Participation Agreement with Prime Health Services

 

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has signed a Provider Participation Agreement ('the Agreement') with Prime Health Services ('Prime Health'), a dynamic healthcare technology US based company focused on delivering innovative, data-driven solutions through its Preferred Provider Organization ('PPO') network.

 

PPO networks were established to bring predictability and consistency to pricing in healthcare. They negotiate on behalf of insurance companies to gain discounted pricing, which benefits healthcare companies by bringing a uniform price in reimbursement within the PPO network and fewer denials from the insurance reimbursement. It also provides Physicians with greater confidence in ordering as there is more certainty in the cost to their patients which in turn provides greater cost transparency to the patient. The insurance plans also benefit from having the PPO networks successfully negotiate this contracted price from both a cost efficiency perspective as well as competitive appeal.

 

Prime Health is one of the fastest-growing preferred provider networks in the US and has more than 850,000 providers across the 50 states, processing around 35 million claims per year. Prime Health's PPO network serves a wide array of clients, including insurance carriers, third-party administrators, self-insured organisations, government entities, and captive insurance groups which provides significant opportunity for Verici Dx to expand its patient scope.

 

Patti Connolly, Chief Operating Officer at Verici Dx, said: "This agreement with Prime Health is an important milestone for Verici Dx, as we accelerate our commercial reach, expanding our patient network and supporting our approach to increased coverage from private payors. We look forward to updating shareholders on additional agreements of this nature in due course."

 

 

Verici Dx plc

 

www.vericidx.com

Sara Barrington, CEO

Via Walbrook PR

 


Singer Capital Markets (Nominated adviser, Joint Broker)

Tel: +44 (0)20 7496 3000

Phil Davies / Sam Butcher


 


Oberon Capital (Joint Broker)

Tel: +44 (0)20 3179 0500

Mike Seabrook


 


Walbrook PR (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com

Alice Woodings / Paul McManus

Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893